Stock of the Day

June 24, 2021

Novavax (NVAX)

$8.21
-$0.03 (-0.4%)
Market Cap: $1.35B

About Novavax

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Today's Trend

Novavax, Inc. (NASDAQ: NVAX) is under pressure today, with investors reacting to a mix of index rebalancing, cautious options activity, and mostly modestly positive analyst revisions.

  • Novavax was removed from several major Russell growth and small-cap indices, which could reduce demand from passive index funds and force benchmark-tracking investors to trim exposure. Novavax (NVAX) Dropped From Major Russell Growth Indices And Why It Matters
  • Options trading turned bearish, with unusually large put buying signaling that some traders are positioning for downside or hedging against further weakness.
  • Zacks Research raised its earnings estimates for Novavax for Q1 2027, Q2 2027, and FY2027 and maintained a Strong-Buy rating, but the revisions were not enough to offset the index-removal headline.
  • Recent commentary also noted Novavax has outperformed some peers despite a recent pullback, suggesting sentiment remains mixed rather than uniformly bearish. Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights

Overall, NVAX appears to be trading lower on concerns that index removals may dampen institutional demand, with bearish options activity reinforcing that view, while analyst estimate increases provide only limited support.

Recent News